AstraZeneca Calquence plus chemoimmunotherapy approved in EU for 1st-line mantle cell lymphoma Ruchika Sharma7 May 2025 12:30 PM ISTCambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the...
Rituximab effective Steroid-Sparing Treatment of steroid-dependent or frequently relapsing nephrotic syndrome: BMC Dr Kartikeya Kohli11 March 2025 8:00 AM ISTA new study published in the journal of BMC Nephrology revealed rituximab to be an effective and safe steroid sparing medication in individuals...
USFDA approves Pfizer Adcetris combination regimen for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ruchika Sharma13 Feb 2025 2:30 PM ISTNew York: Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License...
Merck begins trial evaluating Zilovertamab Vedotin for previously untreated Diffuse Large B-Cell Lymphoma Ruchika Sharma9 Feb 2025 10:30 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial...
USFDA approves AstraZeneca Calquence, bendamustine, rituximab combo for previously untreated mantle cell lymphoma Ruchika Sharma18 Jan 2025 1:30 PM ISTCambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in combination with...
Study finds certain MS therapies may not slow disability progression Dr. Kamal Kant Kohli22 Oct 2024 9:45 PM ISTIn people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened...
Multiple Sclerosis Patients on Rituximab Face Higher COVID-19 Hospitalization: Study Dr. Garima Soni10 Aug 2024 3:30 AM ISTIndia: Patients with multiple sclerosis (MS) treated with rituximab were more prone to COVID-19 infection in comparison to those treated with...
Cyclophosphamide exhibits Long-Term Benefits for Myalgic Encephalomyelitis, Chronic Fatigue Syndrome: Study Medha Baranwal5 Aug 2024 9:00 AM ISTNorway: A comprehensive six-year follow-up of participants from two major clinical trials investigating rituximab and cyclophosphamide for Myalgic...
Dr Reddy's Labs gets positive EMA Committee opinion for proposed Rituximab biosimilar Ruchika Sharma29 July 2024 11:30 AM ISTHyderabad: Dr Reddy's Laboratories Ltd., today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Trial Reveals Long-Term Success of First-Line Rituximab Treatment for Pemphigus Patients Dr.Niharika Harsha B25 March 2024 7:00 PM ISTIn a revolutionary development for pemphigus treatment, a 7-year follow-up study of the Ritux 3 trial has unveiled the remarkable long-term efficacy...
MS drugs taken while breastfeeding may not affect child development, finds new research Dr. Kamal Kant Kohli14 March 2024 9:00 PM ISTCertain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not affect the development of a child...
Ofatumumab subcutaneous injection promising treatment option for refractory pemphigus vulgaris: Study Medha Baranwal4 March 2024 2:00 AM ISTChina: A recent study published in The Journal of Dermatology has suggested ofatumumab to be a promising treatment option for patients with refractory...
